Mirati pulls a rabbit out of its hat, but the conference will serve up three new competitors too.
Hiking the price of a drug before generics appear is a long-enshrined practice, a situation that applies to most of the products singled out by Icer.
Amgen’s AMG 510 disappoints Kras bulls, showing just two new partial responses, in colorectal and appendiceal tumours.
The biggest approval decision in October will involve Novartis’s eye asset Beovu, while Biogen and Alkermes face a key verdict in MS.
Lundbeck needed a deal, but it could struggle against strong competition in migraine.
The latest cut of data from a trial of Amgen’s closely watched Kras inhibitor AMG 510 contains more encouraging signals in lung cancer, though some of the loftiest hopes…
Among small-molecule approaches Europe’s premier oncology conference gives star billing to three Parp inhibitors in ovarian cancer.
With decent efficacy and clean safety in the Orion-11 trial, questions now turn to pricing and whether The Medicines Company will be taken out.